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sels and expansion of extracellular matrix (ECM) in associa-
tion with the outgrowth of fibrovascular epiretinal
membranes at the vitreoretinal interface is the pathological
hallmark in proliferative diabetic retinopathy (PDR), and often
leads to catastrophic loss of vision due to vitreous hemor-
rhage and/or traction retinal detachment. Although the etiol-
ogy of fibrotic disorders is quite diverse, and their
pathogenesis is variable and dependent on the causative
agent or initiating event, a common feature is the presence
of large numbers of myofibroblasts and abnormal accumula-
tion of ECM in the affected tissue(s). Myofibroblasts, the key
cellular mediators of fibrosis, are contractile cells, character-
ized by the expression of a-smooth muscle actin (a-SMA),
and their presence is a marker of progressive fibrosis. They
have the capacity to produce several ECM components
including collagen resulting in fibrosis.1 In the epiretinal
membranes from patients with PDR, inflammatory and fibro-
tic changes are characterized by the presence of inflamma-
tory cells and a-SMA-expressing myofibroblasts in the
stromal compartment.2,3
The origin(s) of myofibroblasts responsible for the exag-
gerated and uncontrolled production of ECM proteins in
PDR epiretinal membranes has not been completely eluci-
dated. Increasing evidence suggests that endothelial cells
may undergo endothelial-to-mesenchymal transition
(EndoMT) or endothelial-to-myofibroblast transition under
physiological, as well as pathological circumstances.4 During
EndoMT, endothelial cells lose their adhesion and apical-
basal polarity to form highly invasive migratory, spindle-
shaped elongated mesenchymal cells. More importantly, bio-
chemical changes accompany these distinct changes in cell
polarity and morphology, including the decreased expression
of endothelial markers, such as CD31, vascular endothelial
(VE)-cadherin, and endothelial nitric oxide synthase (eNOS)
and the acquisition of mesenchymal markers, such as a-
SMA, fibroblast-specific protein-1 (FSP-1, also known as
S100A4), calponin, and smooth muscle protein 22 a or trans-
gelin.4 The cells undergoing transition may contain both
endothelial and mesenchymal properties.
Recently, we explored the hypothesis that EndoMT con-
tributes to the myofibroblast population present in the
epiretinal membranes from patients with PDR. We performed
CD31/FSP-1 and CD31/a-SMA double-labeling to gaininsights into possible EndoMT. We demonstrated for the first
time that endothelial cells in epiretinal fibrovascular mem-
branes from patients with PDR contribute to the emergence
of fibroblasts/myofibroblasts via the process of EndoMT. We
reported that some endothelial cells expressing CD31 co-
express the fibroblast marker FSP-1 and the myofibroblast
marker a-SMA.5 The presence of CD31+/FSP-1+ and
CD31+/a-SMA+ cells indicates an intermediate stage of
EndoMT.6 Our observations suggest that EndoMT plays a
role in creating fibroblasts and myofibroblasts responsible
for fibrosis and progression of PDR. These findings also sug-
gest that EndoMT contributes to the loss of endothelial cells
in PDR epiretinal membranes and the spontaneous regres-
sion of new blood vessels in patients with end-stage PDR.
Finally, we demonstrated that phenotypic changes take place
in human retinal microvascular endothelial cells (HRMEC) fol-
lowing exposure to transforming growth factor-b1 and the
proinflammatory cytokines interleukin-1b and tumor necrosis
factor-a. In the stimulated cell cultures, endothelial cells
changed morphology, down-regulated endothelial cell mark-
ers and upregulated mesenchymal/myofibroblast markers.
These findings corroborate the hypothesis that EndoMT
can contribute to the fibrotic process occurring during PDR.
A greater understanding of the molecular mechanisms
involved in the EndoMT process and the subsequent pharma-
cological blockade of these pathways may represent a novel
therapeutic approach to retard the progression of fibrosis
associated with PDR.Acknowledgment
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